Science Explorer Back to mapMap

Most cited papers from Guangdong General Hospital

What are the most cited papers from Guangdong General Hospital?

The most cited paper from Guangdong General Hospital is "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al., 2009), with 8,331 citations. Next come "A metagenome-wide association study of gut microbiota in type 2 diabetes" (7,088) and "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study" (4,126).

Showing 50 of 60 papers. Every paper with more than 340 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine Open access 19 Aug 2009 8,331
2 A metagenome-wide association study of gut microbiota in type 2 diabetes Junjie Qin et al. · Nature Open access 25 Sep 2012 7,088
3 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou et al. · The Lancet Oncology 25 Jul 2011 4,126
4 Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access Jun 2013 3,429
5 Lung cancer: current therapies and new targeted treatments Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · The Lancet Open access 2 Sep 2016 3,404
6 Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer Tony S.K. Mok, Yi-Long Lung Cancer Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine Open access 6 Dec 2016 3,396
7 Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony S.K. Mok et al. · The Lancet Open access258 authors 4 Apr 2019 3,392
8 CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea R. Doug McEvoy et al. · New England Journal of Medicine 28 Aug 2016 2,096
9 Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology 14 Jan 2014 1,992
10 The gut microbiome in atherosclerotic cardiovascular disease Zhuye Jie et al. · Nature Communications Open access 4 Oct 2017 1,737
11 Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang et al. · The Lancet Oncology 11 Jan 2015 1,596
12 Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology 25 Sep 2017 1,232
13 First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Jean‐Charles Soria et al. · The Lancet 23 Jan 2017 1,168
14 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Carl Zielinski et al. · The Lancet Open access 19 Sep 2009 1,122
15 Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Alexa B. Turke et al. · Cancer Cell Open access 2010 1,078
16 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research 30 Dec 2016 1,012
17 Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 James Chih‐Hsin Yang, Lecia Van Dam Sequist, Sarayut Lucien Geater et al. · The Lancet Oncology 5 Jun 2015 1,002
18 Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) Jian Zhou et al. · Liver Cancer Open access 2020 848
19 Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology 13 May 2015 826
20 The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer Ramón Rami–Porta, Vanessa Bolejack, John Crowley et al. · Journal of Thoracic Oncology Open access 24 Jun 2015 783
21 Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer Yanqi Huang, Zaiyi Liu, Lan He et al. · Radiology 27 Jun 2016 773
22 First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Yi-Long Lung Cancer Wu et al. · Annals of Oncology Open access 23 Jun 2015 741
23 Global cancer surgery: delivering safe, affordable, and timely cancer surgery Richard Sullivan et al. · The Lancet Oncology Open access Sep 2015 709
24 Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) Jian Zhou et al. · Liver Cancer Open access 2018 691
25 Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Simon Patrick Dearden, James Stevens, Yi-Long Lung Cancer Wu et al. · Annals of Oncology Open access 31 May 2013 663
26 COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino et al. · The Lancet Oncology Open access 12 Jun 2020 624
27 Curcumin, Inflammation, and Chronic Diseases: How Are They Linked? Yan He, Yuan Yue, Xi Zheng et al. · Molecules Open access 20 May 2015 611
28 Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography Shengxian Tu, Jelmer Sybren Westra, Junqing Yang et al. · JACC: Cardiovascular Interventions Open access Oct 2016 604
29 Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial Lei Chen et al. · The Lancet Oncology 10 Dec 2011 569
30 Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis Bo Xu, Shengxian Tu, Shubin Qiao et al. · Journal of the American College of Cardiology Open access 31 Oct 2017 558
31 Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Wen‐Zhao Zhong et al. · The Lancet Oncology 22 Nov 2017 538
32 Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma Bin Zhang, Jie Tian, Di Dong et al. · Clinical Cancer Research 9 Mar 2017 534
33 Selective autophagy of intracellular organelles: Recent research advances Wen Li et al. · Theranostics Open access 9 Oct 2020 510
34 Challenges to effective cancer control in China, India, and Russia Paul Edward Goss et al. · The Lancet Oncology Apr 2014 510
35 Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 Mohsen Naghavi et al. · The Lancet Open access2,463 authors Oct 2025 500
36 Central focused convolutional neural networks: Developing a data-driven model for lung nodule segmentation Shuo Wang, Mu Zhou, Zaiyi Liu et al. · Medical Image Analysis Open access 30 Jun 2017 494
37 Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via miR-22 Yuliang Feng, Wei Chieh Huang, Wani Mashhood et al. · PLoS ONE Open access 18 Feb 2014 481
38 Caspase-11–mediated endothelial pyroptosis underlies endotoxemia-induced lung injury Kwong Tai Cheng, Shiqin Xiong, Zhiming Ye et al. · Journal of Clinical Investigation Open access 8 Oct 2017 479
39 Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) Jian Zhou et al. · Liver Cancer Open access102 authors 2023 474
40 Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Tony S.K. Mok, Yi-Long Lung Cancer Wu, Jin Soo Lee et al. · Clinical Cancer Research Apr 2015 472
41 Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Chengbei Zhou et al. · Annals of Oncology Open access 4 Jul 2015 468
42 EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu et al. · OncoImmunology Open access 26 Jul 2017 452
43 YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation Chuanzhao Zhang, Shanzhou� Huang, Hongkai Zhuang et al. · Oncogene 4 May 2020 437
44 Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Yuankai Shi et al. · The Lancet Oncology 13 Aug 2013 426
45 PI3K/Akt and HIF‑1 signaling pathway in hypoxia‑ischemia (Review) Zhen Zhang, Yao Li, Jinhua Yang et al. · Molecular Medicine Reports Open access 9 Aug 2018 422
46 The prevalence of insomnia in the general population in China: A meta-analysis Xiao-Lan Cao, Shi-Bin Wang, Bao‐Liang Zhong et al. · PLoS ONE ReviewOpen access 24 Feb 2017 419
47 Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer Jin Li et al. · JAMA Open access 26 Jun 2018 415
48 Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Jean‐Charles Soria, Yi-Long Lung Cancer Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology 7 Jul 2015 412
49 Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer Rui Li, Rui Zhou, Hui Wang et al. · Cell Death and Differentiation Open access 8 Mar 2019 395
50 Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4 Jing Xiao, Yu Pan, X. H. Li et al. · Cell Death and Disease Open access 23 Jun 2016 375

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.